208 related articles for article (PubMed ID: 37996322)
1. Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines.
Sheng WH; Lin PH; Cheng YC; Wu YY; Hsieh MJ; Yang HC; Chang SY; Chang SC
J Formos Med Assoc; 2024 Mar; 123(3):340-346. PubMed ID: 37996322
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
Kuriyama K; Murakami K; Masuda T; Sugiura K; Sakui S; Schuring RP; Mori M
Vaccine; 2023 Jun; 41(25):3763-3771. PubMed ID: 37198021
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
Kuriyama K; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
Vaccine; 2024 Jan; 42(3):662-670. PubMed ID: 38129286
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM;
Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Madhi SA; Moodley D; Hanley S; Archary M; Hoosain Z; Lalloo U; Louw C; Fairlie L; Fouche LF; Masilela MSL; Singh N; Grobbelaar C; Ahmed K; Benadé G; Bhikha S; Bhorat AE; Bhorat Q; Joseph N; Dheda K; Esmail A; Foulkes S; Goga A; Oommen Jose A; Kruger G; Kalonji DJ; Lalloo N; Lombaard JJ; Lombard Koen A; Kany Luabeya A; Mngqibisa R; Petrick FG; Pitsi A; Tameris M; Thombrayil A; Vollgraaff PL; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Fries L; Robertson A; Neal S; Cho I; Glenn GM; Shinde V;
Lancet HIV; 2022 May; 9(5):e309-e322. PubMed ID: 35489376
[TBL] [Abstract][Full Text] [Related]
8. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Kelly E; Greenland M; de Whalley PCS; Aley PK; Plested EL; Singh N; Koleva S; Tonner S; Macaulay GC; Read RC; Ramsay M; Cameron JC; Turner DPJ; Heath PT; Bernatoniene J; Connor P; Cathie K; Faust SN; Banerjee I; Cantrell L; Mujadidi YF; Belhadef HT; Clutterbuck EA; Anslow R; Valliji Z; James T; Hallis B; Otter AD; Lambe T; Nguyen-Van-Tam JS; Minassian AM; Liu X; Snape MD;
J Infect; 2023 Sep; 87(3):230-241. PubMed ID: 37331429
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
Raiser F; Davis M; Adelglass J; Cai MR; Chau G; Cloney-Clark S; Eickhoff M; Kalkeri R; McKnight I; Plested J; Zhu M; Dunkle LM;
Vaccine; 2023 Sep; 41(41):5965-5973. PubMed ID: 37652823
[TBL] [Abstract][Full Text] [Related]
10. A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Kulkarni PS; Gunale B; Kohli S; Lalwani S; Tripathy S; Kar S; Raut S; Kulkarni P; Apte A; Bavdekar A; Bhalla HL; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Pryor M; Hamilton S; Thakar M; Sannidhi RS; Baranwal P; Bhamare C; Dharmadhikari A; Gupta M; Poonawalla CS; Shaligram U; Kapse D;
Sci Rep; 2023 Oct; 13(1):16579. PubMed ID: 37789040
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Underwood E; Dunkle LM; Madhi SA; Gay CL; Heath PT; Kotloff KL; Smith K; Chau G; Galbiati S; McGarry A; Woo W; Cho I; Alves K; Áñez G; Bennett C; Shinde V; Fries L; Mallory RM; Glenn GM; Toback S
Expert Rev Vaccines; 2023; 22(1):501-517. PubMed ID: 37246757
[TBL] [Abstract][Full Text] [Related]
12. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
Wilkinson B; Patel KS; Smith K; Walker R; Wang C; Greene AM; Smith G; Smith ER; Gurwith M; Chen RT;
Vaccine; 2023 Oct; 41(45):6762-6773. PubMed ID: 37739888
[TBL] [Abstract][Full Text] [Related]
13. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.
Marchese AM; Kalkeri R; Vadivale M; Suntronwong N; Toback S; Poovorawan Y
Expert Rev Vaccines; 2023; 22(1):620-628. PubMed ID: 37386785
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358
[TBL] [Abstract][Full Text] [Related]
15. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
[TBL] [Abstract][Full Text] [Related]
16. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
[TBL] [Abstract][Full Text] [Related]
18. One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
Kuriyama K; Murakami K; Sugiura K; Sakui S; Schuring RP; Masuda T; Mori M
Vaccine; 2024 Feb; 42(6):1319-1325. PubMed ID: 38310018
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
Masuda T; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
Vaccine; 2022 May; 40(24):3380-3388. PubMed ID: 35501178
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
Toback S; Marchese AM; Warren B; Ayman S; Zarkovic S; ElTantawy I; Mallory RM; Rousculp M; Almarzooqi F; Piechowski-Jozwiak B; Bonilla MF; Bakkour AE; Hussein SE; Al Kaabi N
Vaccine; 2024 Mar; 42(7):1777-1784. PubMed ID: 38365482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
